Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 20

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Erectile dysfunction

Recruiting

Study of Botulinum Toxin and Saline Solution for Erectile Dysfunction in Patients Unresponsive to Standard Treatments

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Sodium chloride solution 0.9%
  • Sponsor:Clinica Universidad De Navarra

Paget's disease of the vulva

Recruiting

Study on the Use of Methyl Aminolevulinate and PAGETEX Device for Treating Vulvar Extra-Mammary Paget's Disease in Women

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Methyl Aminolevulinate
  • Sponsor:Centre Hospitalier Universitaire De Lille

Infertility female

Recruiting

Study on Infertility Treatment with Follitropin Alfa and Lutropin Alfa for Women Over 35 with Low Ovarian Response

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Cetrorelix
  • Sponsor:Santiago Dexeus Font Fundacio Privada

Ovarian epithelial cancer

Recruiting

Study on Hyperthermic Intraperitoneal Chemotherapy with Cisplatin for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Unicancer

Breast cancer

Recruiting

Study on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Ovarian cancer

Recruiting

Study of Pembrolizumab with Etoposide and Cisplatin for First-Line Treatment in Patients with Small Cell Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Arcagy Gineco

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Alisertib with Hormone Therapy for Patients with HR+, HER2- Recurrent or Metastatic Breast Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Alisertib Sodium
  • Sponsor:Puma Biotechnology Inc.

HER2 negative breast cancer

Recruiting

Study of Pembrolizumab with Chemotherapy for Patients with HER2-Negative Inflammatory Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Institut Paoli-Calmettes

Breast cancer+4

Recruiting

Study on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Champalimaud Clinical Centre

Prostate cancer+1

Recruiting

Study on Darolutamide, Triptorelin, and Leuprorelin Acetate for Patients with Newly Diagnosed Prostate Cancer and Pelvic Lymph Node Metastases

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:ARTIC

Hydrocele+1

Recruiting

Study on Sclerotherapy for Hydrocele and Spermatocele Using Lauromacrogol 400 and Ethanol in Adult Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ethanol, Anhydrous
  • Sponsor:Region Jamtland Harjedalen

Prostate cancer

Recruiting

Comparison of Short vs Long-term Hormone Therapy with Goserelin, Leuprorelin, or Triptorelin Combined with Radiation for Prostate Cancer Patients After Surgery

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Bicalutamide
  • Sponsor:Instituto De Investigacion En Oncología Radioterapica FEOR

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.